FY2024 EPS Estimates for BioNTech Decreased by HC Wainwright

BioNTech SE (NASDAQ:BNTX) – Analysts at HC Wainwright cut their FY2024 earnings estimates for BioNTech in a note issued to investors on Tuesday, November 5th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($5.24) per share for the year, down from their previous forecast of ($3.92). HC Wainwright currently has a “Buy” rating and a $150.00 price objective on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($2.93) per share. HC Wainwright also issued estimates for BioNTech’s Q4 2024 earnings at $0.06 EPS, Q1 2025 earnings at ($3.42) EPS, Q2 2025 earnings at ($3.50) EPS, Q3 2025 earnings at $0.26 EPS, Q4 2025 earnings at $0.19 EPS and FY2025 earnings at ($6.43) EPS.

A number of other equities research analysts also recently commented on BNTX. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. UBS Group increased their target price on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a report on Wednesday, September 18th. HSBC lifted their price target on BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a report on Monday, October 7th. Deutsche Bank Aktiengesellschaft increased their price objective on BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, September 19th. Finally, Morgan Stanley upgraded BioNTech from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $93.00 to $145.00 in a research note on Tuesday, September 24th. Five research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $134.69.

BioNTech Stock Performance

Shares of BioNTech stock opened at $107.88 on Thursday. The business has a 50-day simple moving average of $111.40 and a 200-day simple moving average of $96.39. The company has a market cap of $25.65 billion, a PE ratio of -51.37 and a beta of 0.26. BioNTech has a one year low of $76.53 and a one year high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of ($1.26) by $2.07. The firm had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. BioNTech had a negative return on equity of 2.34% and a negative net margin of 15.16%. BioNTech’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.73 EPS.

Institutional Trading of BioNTech

Several institutional investors and hedge funds have recently added to or reduced their stakes in BNTX. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of BioNTech by 85.9% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 68,428 shares of the company’s stock worth $6,312,000 after purchasing an additional 31,615 shares during the last quarter. Janney Montgomery Scott LLC acquired a new stake in shares of BioNTech in the 1st quarter worth $314,000. Capstone Investment Advisors LLC purchased a new stake in shares of BioNTech in the first quarter valued at about $263,000. Gallacher Capital Management LLC increased its stake in shares of BioNTech by 24.5% during the first quarter. Gallacher Capital Management LLC now owns 3,262 shares of the company’s stock worth $301,000 after acquiring an additional 642 shares during the period. Finally, SG Americas Securities LLC raised its holdings in BioNTech by 610.5% during the first quarter. SG Americas Securities LLC now owns 70,143 shares of the company’s stock worth $6,471,000 after purchasing an additional 60,270 shares in the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.